Erich Bam
Geschäftsführer bei ViRexx Medical Corp.
Aktive Positionen von Erich Bam
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
ViRexx Medical Corp.
 ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Geschäftsführer | 12.10.2007 | - |
Karriereverlauf von Erich Bam
Ausbildung von Erich Bam
| University of Stellenbosch | Undergraduate Degree |
| University of South Africa | Graduate Degree |
Statistik
International
| Südafrika | 3 |
| Kanada | 2 |
Operativ
| Chief Operating Officer | 1 |
| Undergraduate Degree | 1 |
| Graduate Degree | 1 |
Sektoral
| Consumer Services | 3 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
ViRexx Medical Corp.
ViRexx Medical Corp. Pharmaceuticals: MajorHealth Technology ViRexx Medical Corp. engages in the research, development, and commercialization of biopharmaceutical products for the treatment of cancer and chronic viral infections. It provides drugs for the treatment of ovarian cancer, chronic hepatitis B, hepatitis C and selected solid tumors. It has three platform technologies: The Antiboby-based immunotherapy and Chimigen platforms are designed to educate the immune system to recognize and remove cancer and chronic viruses in the body. The Targeted-Autothrombogenic cancer therapy platform is designed to cut off the blood supply to tumors, which leads to tumor tissue starvation and death. The company is headquartered in Edmonton, Canada. | Health Technology |
